contact@pnhca.org

Blog

Akari Therapeutics Announces Positive Interim Data from Phase 3 Study of Nomacopan in PNH Patients

January 16, 2020

Akari Therapeutics, a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases, announced positive data from Phase 3 of their CAPSTONE study in complement inhibitor naïve, transfusion-dependent PNH patients.

The interim data on the first eight patients, who were all transfusion dependent at entry to the CAPSTONE study, show that all four patients randomized to nomacopan were transfusion independent for the first six months of treatment, while all four patients on standard of care (blood transfusion with or without anticoagulation) remained transfusion dependent.   

Click here to read the company’s full press release.